5302. Cost-Effectiveness of Buprenorphine-Naloxone Versus Extended-Release Naltrexone to Prevent Opioid Relapse.
作者: Sean M Murphy.;Kathryn E McCollister.;Jared A Leff.;Xuan Yang.;Philip J Jeng.;Joshua D Lee.;Edward V Nunes.;Patricia Novo.;John Rotrosen.;Bruce R Schackman.
来源: Ann Intern Med. 2019年170卷2期90-98页
Not enough evidence exists to compare buprenorphine-naloxone with extended-release naltrexone for treating opioid use disorder.
5303. Risk and Risk Factors for Chronic Opioid Use Among Opioid-Naive Patients With Newly Diagnosed Musculoskeletal Pain in the Neck, Shoulder, Knee, or Low Back.
Musculoskeletal pain is a common condition, raising the concern these patients may transition to chronic opioid use. However, the incidence of and risk factors for chronic opioid use among patients with new musculoskeletal pain are not fully understood.
|